Galapagos

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV - American Depositary Shares

Galapagos NV

News

Press Releases

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Appoints Aaron Cox as Chief Financial Officer

Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update

Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Galapagos Creates New Subscription Right Plan

GLPG

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Celcuity

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Cogent Biosciences

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

Amicus Therapeutics

ImmunityBio

IDEAYA Biosciences

Immunovant

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Comments

Galapagos

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL